Why Eli Lilly's Successful Alzheimer's Disease Study Was So Disappointing
Attention for Eli Lilly (NYSE: LLY) has been blowing up since the company announced success for its experimental new Alzheimer's disease drug. Unfortunately, the results strongly suggest that Eli Lilly and Biogen (NASDAQ: BIIB) have a lot more work to do.
How can a clinical trial that succeeded also foreshadow a slow-motion trainwreck? Strap in for some nuance.
Image source: Getty Images.
Source Fool.com
